학술논문

ONCE DAILY NARLAPREVIR (NVR; SCH 900518) AND RITONAVIR (RTV) IN COMBINATION WITH PEGINTERFERON ALFA-2B/RIBAVIRIN (PR) FOR 12 WEEKS PLUS 12 WEEKS PR IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPE 1 (G1): SVR RESULTS FROM NEXT-1, A PHASE 2 STUDY